These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33632218)

  • 41. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India.
    Jain A; Singh PK; Chooramani G; Dixit P; Malhotra HS
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):870-5. PubMed ID: 27287637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
    Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
    BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.
    Knight GM; Gomez GB; Dodd PJ; Dowdy D; Zwerling A; Wells WA; Cobelens F; Vassall A; White RG
    PLoS One; 2015; 10(12):e0145796. PubMed ID: 26717007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High incidence of drug-resistant Mycobacterium tuberculosis in Hainan Island, China.
    Lin M; Zhong Y; Chen Z; Lin C; Pei H; Shu W; Pang Y
    Trop Med Int Health; 2019 Sep; 24(9):1098-1103. PubMed ID: 31278806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.
    Currie CS; Floyd K; Williams BG; Dye C
    BMC Public Health; 2005 Dec; 5():130. PubMed ID: 16343345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.
    Prabowo SA; Gröschel MI; Schmidt ED; Skrahina A; Mihaescu T; Hastürk S; Mitrofanov R; Pimkina E; Visontai I; de Jong B; Stanford JL; Cardona PJ; Kaufmann SH; van der Werf TS
    Med Microbiol Immunol; 2013 Apr; 202(2):95-104. PubMed ID: 23143437
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid molecular diagnostics for multi-drug resistant tuberculosis in India.
    Ramachandran R; Muniyandi M
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):197-204. PubMed ID: 29406800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: A meta-analysis of findings.
    Liu Z; Dong H; Wu B; Zhang M; Zhu Y; Pang Y; Wang X
    J Infect; 2019 Oct; 79(4):349-356. PubMed ID: 31400354
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study.
    Dodd PJ; Mafirakureva N; Seddon JA; McQuaid CF
    Lancet Glob Health; 2022 Jul; 10(7):e1034-e1044. PubMed ID: 35597248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis.
    Eshetie S; Gizachew M; Dagnew M; Kumera G; Woldie H; Ambaw F; Tessema B; Moges F
    BMC Infect Dis; 2017 Mar; 17(1):219. PubMed ID: 28320336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
    Knight GM; Griffiths UK; Sumner T; Laurence YV; Gheorghe A; Vassall A; Glaziou P; White RG
    Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15520-5. PubMed ID: 25288770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of tuberculosis burden in China using a dynamic disease simulation model.
    Mehra M; Cossrow N; Kambili C; Underwood R; Makkar R; Potluri R
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1186-94. PubMed ID: 23827732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
    BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis.
    Dowdy DW; van't Hoog A; Shah M; Cobelens F
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):647-54. PubMed ID: 24903933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
    Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
    Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.